Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Oragenics, Inc. is a development-stage biopharmaceutical company focused on nasal delivery medications for neurology and infectious diseases. Its lead product, ONP-002, aims to treat brain injuries like concussion by rapidly reducing inflammation and swelling via intranasal administration. The company emphasizes proprietary drug formulations, innovative delivery devices, and regulatory pathways to develop and commercialize therapies targeting unmet medical needs in the central nervous system.
This description was generated via AI from an annual report. Updated about 1 year ago.